JPH10175854A - External preparation for skin for improving water (of chinese medicine idea) - Google Patents

External preparation for skin for improving water (of chinese medicine idea)

Info

Publication number
JPH10175854A
JPH10175854A JP26052897A JP26052897A JPH10175854A JP H10175854 A JPH10175854 A JP H10175854A JP 26052897 A JP26052897 A JP 26052897A JP 26052897 A JP26052897 A JP 26052897A JP H10175854 A JPH10175854 A JP H10175854A
Authority
JP
Japan
Prior art keywords
general formula
skin
represented
group
embedded image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP26052897A
Other languages
Japanese (ja)
Inventor
Masanori Kosuge
正規 小菅
Takuo Kosuge
卓夫 小菅
Nobuhiro Ando
信裕 安藤
Yoshie Muramatsu
宜江 村松
Mitsuo Kawai
充夫 河合
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOKUTAAZU KOSUMETEIKUSU KK
Pola Chemical Industries Inc
Original Assignee
DOKUTAAZU KOSUMETEIKUSU KK
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOKUTAAZU KOSUMETEIKUSU KK, Pola Chemical Industries Inc filed Critical DOKUTAAZU KOSUMETEIKUSU KK
Priority to JP26052897A priority Critical patent/JPH10175854A/en
Publication of JPH10175854A publication Critical patent/JPH10175854A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain a skin preparation for external use, improving water (of Chinese medicine idea), useful for stimulating organs controlling the secretion of water in the body to the outside of the body, promoting the secretion of water in the body to the outside of the body and bettering and improving correcting effects on water action, by using estrone, etc. SOLUTION: This skin preparation for external use for improving water uses a compound of the formula (A is N, NR11 , etc.; B is carbonyl, CR12 , etc.; R1 to R12 are each H, OH, an alkyloxy, etc. ; (n) and (m) are 0 or 1) (estrone or estradiol). In the objective skin preparation for external use, the content of the compound of the formula is preferably 0.001-20wt.% based on the total of the skin preparation for external use.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、津液作用の改善に
有益な化粧料、医薬等の皮膚外用剤に関する。
TECHNICAL FIELD The present invention relates to an external preparation for skin such as cosmetics and medicines, which is useful for improving the action of tsukusu.

【0002】[0002]

【従来の技術】漢方思想における気、血、水の考え方
は、その薬理作用の捉え方のユニークさと、漢方薬選択
時の合理的な指標であるために、古くより研究されてき
た。これらの内、気、血の意味するものについては、多
くのことが解明されてきた。例えば、血とは酸素、栄養
等エネルギーを中心とする補給・代謝を表すキーワード
であり、気とは生命活動の恒常性機構の活動状況と生命
活動の原動力の状況を表すキーワードであることが知ら
れている。
2. Description of the Related Art The concept of qi, blood, and water in Chinese medicine has long been studied because of its uniqueness in understanding its pharmacological action and a rational index for selecting Chinese medicine. Of these, many have been elucidated about the meanings of qi and blood. For example, it is known that blood is a keyword that represents the supply and metabolism mainly of energy such as oxygen and nutrition, and ki is a keyword that represents the status of the homeostasis of life activity and the status of the driving force of life activity. Have been.

【0003】しかし、水(津液)の働きについては老廃
物の代謝・排泄作用のみしか知られておらず、気・血・
水の論理体型において遅れて認識された為、その真の作
用(津液作用)の解明は未完であった。また、津液作用
と現代医学で認識されている種々の薬理作用等との関係
や津液の現代医学における役割などはあまり知られてお
らず、現代医学の分野における津液作用の解明及び津液
作用の改善をもたらす化粧料、医薬等の開発が望まれて
いた。
[0003] However, only the metabolism and excretion of waste products is known for the function of water (tsu liquor).
Since the recognition was delayed in the logical form of water, the elucidation of its true action (Tsukumi action) was incomplete. Also, little is known about the relationship between the pulp action and the various pharmacological actions recognized in modern medicine, and the role of pulp in modern medicine. The development of cosmetics, medicines, etc. that bring about such problems has been desired.

【0004】[0004]

【発明が解決しようとする課題】本発明はこのような状
況を踏まえてなされたものであり、津液の真の作用を明
らかにし、津液作用の改善に用いられる皮膚外用剤を提
供することを課題とする。
DISCLOSURE OF THE INVENTION The present invention has been made in view of such circumstances, and has as its object to clarify the true function of a tsuju and to provide an external preparation for skin used to improve the action of a tsuku. And

【0005】[0005]

【課題を解決するための手段】本発明者等は、このよう
な状況に鑑み、津液の真の作用を求めて鋭意研究を重ね
た結果、津液作用が、ある種の物質の働きによって水分
の体外への分泌を司る器官を刺激し、体内水分の体外へ
の分泌を促進させる作用を意味していることを見いだし
た。そして、そのような分泌器官を刺激し津液作用を促
進・改善しうる物質について検討した結果、本発明を完
成した。
Means for Solving the Problems In view of such a situation, the present inventors have conducted intensive studies in search of the true function of tsuju. It was found that it stimulates the organs responsible for extracorporeal secretion and promotes the secretion of body water out of the body. Then, as a result of examining substances capable of stimulating such secretory organs and promoting / improving the action of the pulp, the present invention was completed.

【0006】すなわち、本発明は、下記一般式(I)で
表される化合物及びその生理的に許容される塩からなる
群から選ばれる1種又は2種以上を有効成分とする津液
改善用皮膚外用剤を提供するものである。
[0006] That is, the present invention provides a skin for improving a tsunami containing one or more active ingredients selected from the group consisting of a compound represented by the following general formula (I) and a physiologically acceptable salt thereof. It provides an external preparation.

【0007】[0007]

【化12】 Embedded image

【0008】[式(I)中、Aは窒素原子、−NR
11−、−CR11−又は−CHR11−を表し、Bはカルボ
ニル基、−CR12−又は−CHR12−を表し、R1
2、R3、R4、R5、R6、R7、R8、R9、R10
11、及びR12はそれぞれ独立に水素原子、水酸基、ア
ルキルオキシ基、アシルオキシ基、カルボニル基を形成
していてもよい酸素原子、エステル化されていてもよい
カルボキシル基、カルボニル基又は同一化合物内の他の
原子と結合していてもよく、また結合する炭素原子とは
多重結合していてもよい低鎖長アルキル基を表し、n、
mはそれぞれ独立に0又は1を表す。]
[In the formula (I), A is a nitrogen atom, -NR
11 -, - CR 11 - or -CHR 11 -, B stands carbonyl group, -CR 12 - or -CHR 12 - represents, R 1,
R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 ,
R 11 and R 12 each independently represent a hydrogen atom, a hydroxyl group, an alkyloxy group, an acyloxy group, an oxygen atom which may form a carbonyl group, a carboxyl group which may be esterified, a carbonyl group or the same compound. And a carbon atom to be bonded may represent a low-chain-length alkyl group which may be multiple-bonded, and n,
m represents 0 or 1 each independently. ]

【0009】本発明者らは、津液作用が、真皮から表皮
への水分分泌を促進し表皮に十分な水分を保持させるこ
とによって起こる美肌作用、アトピー性皮膚炎、湿疹、
皮膚真菌症、疣贅、色素沈着症、尋常性乾癬、老人性乾
皮症、老人性角化腫、火傷等の各種皮膚疾患治療作用、
発毛促進作用、発汗促進作用、胃壁、腎臓、腸管での水
分分泌を促進させることによって起こる消化液分泌促進
作用、利尿作用、便通促進作用にかかわる作用であるこ
とを見出した。
[0009] The present inventors have found that the tsuyu action promotes the secretion of water from the dermis to the epidermis and causes the epidermis to retain sufficient moisture, resulting in a beautiful skin action, atopic dermatitis, eczema,
Dermatomycosis, warts, pigmentation, psoriasis vulgaris, senile xeroderma, senile keratoma, therapeutic effects on various skin diseases such as burns,
It has been found that the action is related to a hair growth promoting action, a sweat promoting action, a digestive juice secretion promoting action, a diuretic action and a bowel movement promoting action caused by promoting water secretion in the stomach wall, kidney and intestinal tract.

【0010】すなわち、漢方生薬の薬効分類を詳細に検
討し、現代医薬分類との対比を行った結果、水(津液)
が関与すると言われている、しゃ下、利水、消導、補陰
と言った薬草群の作用が現代医薬品分類における美肌作
用、アトピー性皮膚炎治療作用、湿疹で代表される皮膚
炎群治療作用、皮膚真菌症治療作用、疣贅治療作用、肝
炎で代表される色素沈着症治療作用、尋常性乾癬治療
症、老人性乾皮症、老人性角化腫治療作用、物理的原因
による皮膚損傷治療作用、発毛促進作用、消化液分泌促
進作用、発汗促進作用、利尿作用、便通促進作用と係わ
りが深いことを見いだした。
That is, the medicinal classification of Chinese herbal medicines was examined in detail, and compared with modern medicine classifications.
It is said that the effects of the herbs such as shampoo, irrigation, conduction and prosthesis are related to beautiful skin effect, atopic dermatitis treatment, and dermatitis group treatment represented by eczema in the modern pharmaceutical classification. , Dermatomycosis treatment, wart treatment, pigmentation such as hepatitis, psoriasis vulgaris, senile xeroderma, senile keratoma treatment, skin damage treatment due to physical causes It has been found that it is closely related to the action, the hair growth promoting action, the digestive juice secretion promoting action, the sweating promoting action, the diuretic action and the bowel movement promoting action.

【0011】この知見をもとに種々の物質について美肌
作用、アトピー性皮膚炎治療作用、発毛促進作用、湿疹
の治療作用、消化液分泌促進作用、発汗促進作用を指標
にスクリーニングを重ねたところ、上記一般式(I)で
表される化合物及びその生理的に許容される塩からなる
群から選ばれる化合物がこのような作用に優れることを
見いだした。更に驚くべきことに、上記一般式(I)で
表される化合物及びその生理的に許容される塩からなる
群から選ばれる化合物を外用投与することにより、胃酸
等の消化液の分泌が促されるなどの効果があることを見
出し、本発明を完成させるに至った。
Based on this finding, screening was carried out on various substances based on the indicators of skin beautiful action, atopic dermatitis treatment action, hair growth promotion action, eczema treatment action, digestive juice secretion promotion action and sweating promotion action. It has been found that a compound selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof is excellent in such action. Even more surprisingly, by externally administering a compound selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof, secretion of digestive juice such as stomach acid is promoted. The present inventors have found that the present invention has such effects as described above, and have completed the present invention.

【0012】上記一般式(I)で表される化合物又はそ
の生理的に許容される塩が経皮吸収促進作用、肝機能の
改善や免疫機能の改善作用を有していることは知られて
いるものの、真の意味での津液改善作用があることは知
る余地もなかった。更に、上記一般式(I)で表される
化合物又はその生理的に許容される塩が美肌作用、アト
ピー性皮膚炎、湿疹、皮膚真菌症、疣贅、色素沈着症、
尋常性乾癬、老人性乾皮症、老人性角化腫、火傷等の皮
膚疾患治療作用、発毛促進作用、発汗促進作用、消化液
分泌促進作用、利尿作用、便通促進作用を有することは
全く知られていなかった。
It is known that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof has a percutaneous absorption promoting action, a liver function improving action and an immune function improving action. However, there was no way to know that there was a true improvement of the tsuyu. Further, the compound represented by the above general formula (I) or a physiologically acceptable salt thereof may be used as a beautifying agent, atopic dermatitis, eczema, dermatomycosis, warts, pigmentation,
It has no action to treat skin diseases such as psoriasis vulgaris, senile xeroderma, senile keratoma, burns, etc., hair growth promoting action, sweat sweat promoting action, digestive juice secretion promoting action, diuretic action, and bowel movement promoting action. Was not known.

【0013】[0013]

【発明の実施の形態】以下に、本発明の実施の形態を説
明する。本発明の津液改善用皮膚外用剤は、上記一般式
(I)で表される化合物及びその生理的に許容される塩
からなる群から選ばれる1種又は2種以上を有効成分と
する。式(I)中、Aは窒素原子、−NR11−、−CR
11−又は−CHR11−を表し、Bはカルボニル基、−C
12−又は−CHR12−を表し、R1、R2、R3、R4
5、R6、R7、R8、R9、R10、R11、及びR12はそ
れぞれ独立に水素原子、水酸基、アルキルオキシ基、ア
シルオキシ基、カルボニル基を形成していてもよい酸素
原子、エステル化されていてもよいカルボキシル基、カ
ルボニル基又は同一化合物内の他の原子と結合していて
もよく、また結合する炭素原子とは多重結合していても
よい低鎖長アルキル基を表し、n、mはそれぞれ独立に
0又は1を表す。ここで、低鎖長アルキル基としては、
好ましくは炭素数1〜10の直鎖又は分岐のアルキル基
であり、更に好ましくは炭素数1〜4のものである。
Embodiments of the present invention will be described below. The skin external preparation for tsumuage improvement of the present invention contains, as an active ingredient, one or more selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof. In formula (I), A is a nitrogen atom, -NR 11 -, - CR
11 - or -CHR 11 -, B stands carbonyl group, -C
R 12 — or —CHR 12 — represents R 1 , R 2 , R 3 , R 4 ,
R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 each independently represent a hydrogen atom, a hydroxyl group, an alkyloxy group, an acyloxy group, or an oxygen which may form a carbonyl group. Atom, a carboxyl group which may be esterified, a carbonyl group or a low chain alkyl group which may be bonded to another atom in the same compound and which may be multiple-bonded to the carbon atom to be bonded. And n and m each independently represent 0 or 1. Here, as the low chain length alkyl group,
It is preferably a straight-chain or branched alkyl group having 1 to 10 carbon atoms, and more preferably 1 to 4 carbon atoms.

【0014】一般式(I)で表される化合物としては、
具体的にはエストロン、エストラジオール、エストリオ
ール、アンドロステロン、スチルベステロール、3,4
−ビス(4−ヒドロキシフェニル)ヘキサン−2,4−
ジエン、4−(N−(4−ヒドロキシフェニル)アミノ
カルボニル)フェノール、デオキシスチルベステロー
ル、3−(4−ヒドロキシフェニル)−4−フェニルヘ
キサン−2,4−ジエン、又は4−(N−フェニルアミ
ノカルボニル)フェノール及びこれらのアシル化物、ア
ルキルエーテル体等の誘導体が例示でき、これらがいず
れも使用できる。このうちアシル化体は、アルカリ存在
下酸クロライドと反応させることにより容易に得ること
ができる。アルリキルエーテル体は、例えばヨウ化メチ
ルなどのアルキルハライドとアルカリ存在下に反応させ
ることにより容易に得ることができる。これらのうち特
に好ましいものは、下記一般式(II)で表されるエス
トロン、下記一般式(III)で表されるエストラジオ
ール、下記一般式(IV)で表されるエストリオール、
下記一般式(V)で表されるアンドロステロン、下記一
般式(VI)で表されるスチルベステロール、下記一般
式(VII)で表される3,4−ビス(4−ヒドロキシ
フェニル)ヘキサン−2,4−ジエン、下記一般式(V
III)で表される4−(N−(4−ヒドロキシフェニ
ル)アミノカルボニル)フェノール、下記一般式(I
X)で表されるデオキシスチルベステロール、下記一般
式(X)で表される3−(4−ヒドロキシフェニル)−
4−フェニルヘキサン−2,4−ジエン、もしくは下記
一般式(XI)で表される4−(N−フェニルアミノカ
ルボニル)フェノール又はこれらのアシル化物、アルキ
ルエーテル体等の誘導体である。
The compound represented by the general formula (I) includes
Specifically, estrone, estradiol, estriol, androsterone, stilbesterol, 3,4
-Bis (4-hydroxyphenyl) hexane-2,4-
Diene, 4- (N- (4-hydroxyphenyl) aminocarbonyl) phenol, deoxystilbestrol, 3- (4-hydroxyphenyl) -4-phenylhexane-2,4-diene, or 4- (N-phenyl) Derivatives such as aminocarbonyl) phenol and acylated products and alkyl ethers thereof can be exemplified, and all of them can be used. Among them, the acylated product can be easily obtained by reacting with an acid chloride in the presence of an alkali. The alkyl ether compound can be easily obtained by reacting with an alkyl halide such as methyl iodide in the presence of an alkali. Among them, particularly preferred are estrone represented by the following general formula (II), estradiol represented by the following general formula (III), estriol represented by the following general formula (IV),
Androsterone represented by the following general formula (V), stilbesterol represented by the following general formula (VI), 3,4-bis (4-hydroxyphenyl) hexane represented by the following general formula (VII) 2,4-diene having the following general formula (V
4- (N- (4-hydroxyphenyl) aminocarbonyl) phenol represented by the formula (III):
Deoxystilbestrol represented by X), 3- (4-hydroxyphenyl)-represented by the following general formula (X)
4-phenylhexane-2,4-diene, 4- (N-phenylaminocarbonyl) phenol represented by the following general formula (XI), or an acylated product thereof, or a derivative such as an alkyl ether compound.

【0015】[0015]

【化13】 Embedded image

【0016】[0016]

【化14】 Embedded image

【0017】[0017]

【化15】 Embedded image

【0018】[0018]

【化16】 Embedded image

【0019】[0019]

【化17】 Embedded image

【0020】[0020]

【化18】 Embedded image

【0021】[0021]

【化19】 Embedded image

【0022】[0022]

【化20】 Embedded image

【0023】[0023]

【化21】 Embedded image

【0024】[0024]

【化22】 Embedded image

【0025】上記一般式(I)で表される化合物の生理
的に許容される塩とは、例えば、ナトリウム、カリウム
等のアルカリ金属塩、カルシウム、マグネシウム等のア
ルカリ土類金属塩、アンモニウム塩、トリエチルアミン
やトリエタノールアミン等の有機アミン塩、リジンやア
ルギニン等の塩基性アミノ酸塩等が好ましく例示でき
る。これらの対塩基は1種でも2種以上を組み合わせて
用いても構わない。
The physiologically acceptable salts of the compounds represented by the above general formula (I) include, for example, alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, and ammonium salts. Preferred are organic amine salts such as triethylamine and triethanolamine, and basic amino acid salts such as lysine and arginine. These counterbases may be used alone or in combination of two or more.

【0026】一般式(I)で表される化合物及び/又は
その生理的に許容される塩はいずれも市販されており入
手可能である。本発明の皮膚外用剤としては、基礎化粧
料やメークアップ化粧料、頭髪用化粧料、浴用剤などの
化粧料や、抗炎症外用剤等の皮膚外用医薬組成物が例示
できる。本発明の皮膚外用剤における上記一般式(I)
で表される化合物又はその生理的に許容される塩の好ま
しい含有量は、皮膚外用剤全体に対し0.001〜20
重量%であり、より好ましくは0.01〜10重量%で
あり、更に好ましくは0.01〜5重量%である。
The compound represented by the general formula (I) and / or a physiologically acceptable salt thereof are all commercially available. Examples of the external preparation for skin of the present invention include cosmetics such as basic cosmetics, make-up cosmetics, hair cosmetics, bath preparations and the like, and skin external pharmaceutical compositions such as anti-inflammatory external preparations. Formula (I) in the external preparation for skin of the present invention
The preferable content of the compound represented by the formula or a physiologically acceptable salt thereof is 0.001 to 20 with respect to the whole skin external preparation.
%, More preferably 0.01 to 10% by weight, even more preferably 0.01 to 5% by weight.

【0027】本発明の皮膚外用剤は、上記一般式(I)
で表される化合物又はその生理的に許容される塩以外
に、化粧料、皮膚外用医薬組成物等で通常用いられてい
る任意成分を含有することができる。このような任意成
分としては、ワセリンやマイクロクリスタリンワックス
等のような炭化水素類、ホホバ油やゲイロウ等のエステ
ル類、牛脂、オリーブ油等のトリグリセライド類、セタ
ノール、オレイルアルコール等の高級アルコール類、ス
テアリン酸、オレイン酸等の脂肪酸、グリセリンや1,
3−ブタンジオール等の多価アルコール類、非イオン界
面活性剤、アニオン界面活性剤、カチオン界面活性剤、
両性界面活性剤、エタノール、カーボポール等の増粘
剤、防腐剤、紫外線吸収剤、抗酸化剤、色素、粉体類等
が例示できる。これらの任意成分と上記一般式(I)で
表される化合物又はその生理的に許容される塩とを常法
に従って処理することにより、本発明の皮膚外用剤を製
造することができる。
The external preparation for skin of the present invention is preferably prepared by the above-mentioned general formula (I)
In addition to the compound represented by the formula (I) or a physiologically acceptable salt thereof, the composition may contain optional components commonly used in cosmetics, skin external pharmaceutical compositions and the like. Such optional components include hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax, triglycerides such as tallow, olive oil, higher alcohols such as cetanol and oleyl alcohol, and stearic acid. , Fatty acids such as oleic acid, glycerin and 1,
Polyhydric alcohols such as 3-butanediol, nonionic surfactants, anionic surfactants, cationic surfactants,
Examples include amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, pigments, and powders. The external preparation for skin of the present invention can be produced by treating these optional components with the compound represented by the above general formula (I) or a physiologically acceptable salt thereof in a conventional manner.

【0028】本発明の津液改善用皮膚外用剤は、津液作
用の促進・改善に用いられる。津液作用は、その発現形
態としてしゃ下作用、利水作用、補陰作用、消導作用と
して生体に発現することが知られている。これらの作用
を有する漢方生薬としては、しゃ下作用であれば、ダイ
オウ、バンシャヨウ、ロカイ、マシニン、ケンゴシ、カ
ンスイ、ゲンカ、ゾクズイシ、ウキュウコンピ等が知ら
れており、利水作用を有する漢方生薬としては、チョレ
イ、ブクリョウ、タクシャ、インチンコウ、ヨクイニ
ン、トウカニン、ジフシ、トウキヒ、キンセンソウ等が
知られており、補陰作用を有する漢方生薬としては、シ
ャジン、セイヨウジン、テンモンドウ、バクモンドウ、
セッコク、ギョクチク、ヒャクゴウ、ソウキセイ、カン
レンソウ、ジョテイシ、ゴマ、コクズ、キバン、ベッコ
ウ等が知られており、消導作用を有する漢方生薬として
は、サンザシ、クレンコンピ、ヒシ、カクシツ、ライガ
ン、ビンロウジ、ナンカシ、タイサン等が知られてい
る。
The skin external preparation for improving tidal fluid of the present invention is used for promoting / improving the action of liquor. It is known that the tsuju action is expressed in a living body as a mode of expression, such as a shampooing action, a water-supplying action, a prosthesis action, and a conduction action. As a herbal crude drug having these effects, if it is a shampooing effect, rhubarb, banshayou, rokai, machinin, kengoshi, Kansui, Genka, Zokuzuishi, kyukyu compi, etc. Chorei, Bukuryo, Taksha, Inchinko, Jokuinin, Toukanin, Difushi, Tokhihi, Kinsenso and the like are known, and as herbal crude drugs having a prosthetic effect, Shajin, Eurasia, Tenmondou, Bakumondou,
Ginseng, arctic, antelope, sycamore, renren, jotenishi, sesame, kokuzu, kiban, bekko are known, and as a herbal crude drug having an antidepressant effect, hawthorn, krenkonpi, hishi, kakushitsu, reigan, areca, nankashi, Taisan and the like are known.

【0029】これらについての文献等を調べてみると、
美肌作用、発毛促進作用、抗アレルギー作用、抗炎症作
用、消化促進作用等の薬理作用が重複していることが見
出された。ここに本発明者等は注目し、「水」(津液)
の作用は現代医学における美肌作用、アトピー性皮膚
炎、湿疹、皮膚真菌症、疣贅、色素沈着症、尋常性乾
癬、老人性乾皮症、老人性角化腫、火傷等の皮膚疾患の
治療作用、発毛促進作用、吹き出物の治療作用、消化液
分泌促進作用、発汗促進作用、利尿作用、便通促進作用
等を指標とすることができることを見出した。これらの
作用の一つを有する物質は、大なり小なり他の作用も有
している。したがって、これらの作用の一つを指標にす
るスクリーニングを行えば、他の作用の推定を行うこと
ができる。
Examining the literature and the like about these,
It has been found that pharmacological actions such as beautifying action, hair growth-promoting action, anti-allergic action, anti-inflammatory action, and digestion promoting action overlap. Here, the present inventors pay attention, and consider "water" (Tsu liquid).
Works in modern medicine to treat skin disorders such as skin beautification, atopic dermatitis, eczema, dermatomycosis, warts, pigmentation, psoriasis vulgaris, senile xeroderma, senile keratoma and burns It has been found that the action, the hair growth promoting action, the therapeutic action of pimples, the digestive juice secretion promoting action, the sweat promoting action, the diuretic action, the bowel movement promoting action and the like can be used as indices. Substances that have one of these actions also have greater or lesser other actions. Therefore, if screening is performed using one of these actions as an index, other actions can be estimated.

【0030】本発明の津液改善用皮膚外用剤は、美肌作
用、アトピー性皮膚炎治療作用、湿疹で代表される皮膚
炎群治療作用、皮膚真菌症治療作用、疣贅治療作用、肝
炎で代表される色素沈着症治療作用、尋常性乾癬治療
症、老人性乾皮症、老人性角化腫治療作用、物理的原因
による皮膚損傷治療作用、発毛促進作用、消化液分泌促
進作用、発汗促進作用、便通促進作用、及び排尿促進
(利尿)作用からなる群から選ばれる少なくとも一つを
改善する作用を有しており、これを用いることにより、
肌の衰えの防止と改善、アトピー性皮膚炎の治療と発症
・悪化の防止、発毛の促進と抜け毛の予防、湿疹の改善
と悪化の予防、便通の促進と排尿の促進等の効果が発揮
される。
The skin external preparation for improving tsukusu according to the present invention is represented by a skin beautifying effect, an atopic dermatitis treatment effect, a dermatitis group treatment effect represented by eczema, a dermatomycosis treatment effect, a wart treatment effect, and hepatitis. Therapeutic action for pigmentation disease, psoriasis vulgaris, senile xeroderma, senile keratoma, skin damage treatment due to physical causes, hair growth promoting action, digestive secretion promoting action, sweat promoting action Has a function to improve at least one selected from the group consisting of a bowel movement promoting action, and a urination promoting (diuretic) action, and by using this,
Exhibits the effects of preventing and improving skin deterioration, treating atopic dermatitis and preventing the onset and worsening, promoting hair growth and preventing hair loss, improving and preventing eczema, promoting bowel movements and promoting urination. Is done.

【0031】本発明の皮膚外用剤の好ましい投与量は、
疾病の種類や患者の特性によって異なるが、適当量を患
部皮膚や健常皮膚の一部又は全体に適当量一日一回乃至
は数回塗布すればよい。
The preferred dosage of the external preparation for skin of the present invention is
The appropriate amount may be applied once or several times a day to a part or the whole of the affected skin or healthy skin, depending on the kind of the disease and the characteristics of the patient.

【0032】取り分け本発明で注目すべきことは、本発
明の上記一般式(I)で表される化合物又はその生理的
に許容される塩は、経皮投与によって胃酸などの消化液
の分泌が促進される等の効果を有する点であり、経皮投
与でこのような作用を同時に期待しうる物質は未だ知ら
れていない。
It should be noted that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof according to the present invention is capable of secreting digestive juices such as gastric acid by transdermal administration. It has the effect of being accelerated and the like, and a substance that can simultaneously expect such an effect by transdermal administration has not been known yet.

【0033】[0033]

【実施例】以下に、本発明の実施例を説明する。尚、表
中の処方の数値の単位はすべて重量部である。
Embodiments of the present invention will be described below. In addition, the unit of the numerical value of the prescription in the table is all parts by weight.

【0034】[0034]

【実施例1〜5】 <配合例>下記表1に示す処方に従って皮膚外用剤(ク
リーム)を作成した。即ち、(イ)、(ロ)、(ハ)の
各成分群をそれぞれ80℃で加熱し、(イ)をよく混練
し、これに(ロ)を加えて希釈し、更にこれに(ハ)を
徐々に加えて乳化し、撹拌冷却して皮膚外用剤を得た。
このものは安全性も高く、下記試験例に示すように優れ
た津液作用を有するので、医薬組成物としても化粧料と
しても有用である。
Examples 1 to 5 <Formulation Examples> Skin external preparations (creams) were prepared according to the formulations shown in Table 1 below. That is, each of the component groups (a), (b) and (c) is heated at 80 ° C., (a) is kneaded well, (b) is added thereto, diluted, and (c) Was gradually added and emulsified, followed by stirring and cooling to obtain a skin external preparation.
It is highly safe and has an excellent essence as shown in the following test examples, and is therefore useful as a pharmaceutical composition and as a cosmetic.

【0035】[0035]

【表1】 [Table 1]

【0036】[0036]

【実施例6〜10】 <配合例>下記表2に示す処方に従って皮膚外用剤(ク
リーム)を作成した。即ち、(イ)、(ロ)、(ハ)の
各成分群をそれぞれ80℃で加熱し、(イ)をよく混練
し、これに(ロ)を加えて希釈し、更にこれに(ハ)を
徐々に加えて乳化し、撹拌冷却して皮膚外用剤を得た。
このものは安全性も高く、下記試験例に示すように優れ
た津液作用を有するので、医薬組成物としても化粧料と
しても有用である。
Examples 6 to 10 <Formulation Examples> Skin external preparations (creams) were prepared according to the formulations shown in Table 2 below. That is, each of the component groups (a), (b) and (c) is heated at 80 ° C., (a) is kneaded well, (b) is added thereto, diluted, and (c) Was gradually added and emulsified, followed by stirring and cooling to obtain a skin external preparation.
It is highly safe and has an excellent essence as shown in the following test examples, and is therefore useful as a pharmaceutical composition and as a cosmetic.

【0037】[0037]

【表2】 [Table 2]

【0038】[0038]

【実施例11〜15】 <配合例>下記表3に示す成分を用いその処方に従っ
て、皮膚外用剤(軟膏)を作成した。即ち、各処方成分
をニーダーに秤込み、よく混練して軟膏を得た。
Examples 11 to 15 <Formulation Example> A skin external preparation (ointment) was prepared using the components shown in Table 3 below and according to the formulation. That is, each prescription component was weighed into a kneader and kneaded well to obtain an ointment.

【0039】[0039]

【表3】 [Table 3]

【0040】[0040]

【実施例16〜20】 <配合例>下記表4に示す成分を用いてその処方に従っ
て、頭髪用皮膚外用剤(ヘアトニック)を作成した。即
ち、各処方成分を室温で撹拌可溶化し、ヘアトニックを
得た。
Examples 16 to 20 <Formulation Examples> Using the ingredients shown in Table 4 below, external preparations for hair skin (hair tonics) were prepared according to the formulation. That is, each formulation component was stirred and solubilized at room temperature to obtain a hair tonic.

【0041】[0041]

【表4】 [Table 4]

【0042】[0042]

【実施例21〜25】 <配合例>下記表5に示す成分を用いその処方に従っ
て、浴用剤を作成した。即ち、各処方成分をニーダーで
混練し浴用剤を得た。
Examples 21 to 25 <Formulation Examples> Bath ingredients were prepared using the components shown in Table 5 below and according to the formulations. That is, the respective components were kneaded with a kneader to obtain a bath agent.

【0043】[0043]

【表5】 [Table 5]

【0044】[0044]

【実施例26】 <試験例1:美肌改善作用>肌荒れに悩む22〜32歳
のパネラー1群10名が、上記実施例1〜7の皮膚外用
剤(0.02g)を1日朝晩2回ずつ2ヶ月間患部に塗
布し、肌荒れの改善効果を評価した。評価の基準は、非
常に改善した(評点5)〜改善しない(評点0)、とし
た。対照としては、本発明の有効成分である上記一般式
(I)で表される化合物又はその生理的に許容される塩
を水で置換したものを用いた。結果を平均評点として表
6に示す。これより、本発明の皮膚外用剤が肌荒れを改
善する作用を有すること、即ち、美肌作用を有すること
がわかる。これにより、本発明の上記一般式(I)で表
される化合物又はその生理的に許容される塩がこのよう
な作用を有することがわかる。
Example 26 <Test Example 1: Improving Skin Beauty> Ten panelists, 22 to 32 years old, suffering from rough skin, applied the skin external preparations (0.02 g) of Examples 1 to 7 twice daily in the morning and evening. Each was applied to the affected area for two months, and the effect of improving skin roughness was evaluated. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control, a compound represented by the above general formula (I), which is an active ingredient of the present invention, or a physiologically acceptable salt thereof was replaced with water. The results are shown in Table 6 as average scores. This indicates that the external preparation for skin of the present invention has an effect of improving rough skin, that is, has a skin beautiful effect. This shows that the compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof has such an effect.

【0045】[0045]

【表6】 [Table 6]

【0046】[0046]

【実施例27】 <試験例2:発毛促進作用>C3Hマウス1群5匹の背
部を剃毛し、下記表7に示す検体10mgを生理食塩水
200μlに溶解又は分散させて塗布し、その後の毛の
生え方を観察して発毛促進作用を評価した。対照はベヒ
クルの生理食塩水のみとした。評価の基準は、++(評
点4):対照に比べて著しく早い、+(評点2):対照
に比べて早い、±(評点1):対照に比べてやや早い、
−(評点0):対照に比べて早くない、とした。結果を
平均評点として表7に示す。これより、本発明の皮膚外
用剤の有効成分である上記一般式(I)で表される化合
物又はその生理的に許容される塩は発毛促進作用に優れ
ることがわかる。
Example 27 <Test Example 2: Hair growth promoting action> The back of a group of 5 C3H mice was shaved, and 10 mg of a sample shown in Table 7 below was dissolved or dispersed in 200 µl of physiological saline and applied. The hair growth promoting effect was evaluated by observing the hair growth. The control was vehicle saline only. The evaluation criteria are ++ (score 4): significantly earlier than the control, + (score 2): earlier than the control, ± (score 1): slightly earlier than the control,
-(Score 0): Not earlier than control. The results are shown in Table 7 as average scores. This shows that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the external preparation for skin of the present invention, is excellent in hair growth promoting action.

【0047】[0047]

【表7】 [Table 7]

【0048】尚、表7中の誘導体1〜4は以下に示す方
法により製造したものである。 (1)エストラジオールのアシル化 ペンタデカン酸1gをクロロホルム100mlに溶か
し、これに10mlの塩化チオニルを加え室温で1時間
撹拌し減圧溜去し酸クロライドを得た。これをクロロホ
ルム100mlに溶かし、氷冷下これに500mgのエ
ストラジオールを1000mlのクロロホルムと20m
lのトリエチルアミンに溶解した溶液に滴下して加え
た。室温に戻して2時間撹拌した後、溶媒を溜去しシリ
カゲルカラムクロマトグラフィー(溶出溶媒;ベンゼ
ン:クロロホルム:メタノール=50:50:0→0:
100:0→0:80:20)で精製し、121mgの
3−ペンタデカノイルオキシエストラジオール(誘導体
1)と78mgの17−ペンタデカノイルオキシエスト
ラジオール(誘導体2)と256mgのエストラジオー
ルジペンタデナノエート(誘導体3)を得た。
The derivatives 1 to 4 in Table 7 were produced by the following methods. (1) Acylation of estradiol 1 g of pentadecanoic acid was dissolved in 100 ml of chloroform, 10 ml of thionyl chloride was added thereto, the mixture was stirred at room temperature for 1 hour, and distilled under reduced pressure to obtain acid chloride. This was dissolved in 100 ml of chloroform, and 500 mg of estradiol was added thereto with 1000 ml of chloroform under ice-cooling for 20 ml.
l was added dropwise to a solution dissolved in triethylamine. After returning to room temperature and stirring for 2 hours, the solvent was distilled off and silica gel column chromatography (elution solvent: benzene: chloroform: methanol = 50: 50: 0 → 0:
100: 0 → 0: 80: 20), 121 mg of 3-pentadecanoyloxyestradiol (derivative 1), 78 mg of 17-pentadecanoyloxyestradiol (derivative 2) and 256 mg of estradiol dipentadenanoate (Derivative 3) was obtained.

【0049】(2)エストロンのアシル化 エストロン270mgをピリジン50mlに溶かし、氷
冷下無水酢酸10mlを加えた。室温に戻し24時間撹
拌し溶媒を溜去した後、シリカゲルカラムクロマトグラ
フィー(溶出溶媒;ヘキサン:酢酸エチル=100:0
→50:50→30:70→0:100)で精製し、2
98mgのエストロンアセテート(誘導体4)を得た。
(2) Acylation of estrone 270 mg of estrone was dissolved in 50 ml of pyridine, and 10 ml of acetic anhydride was added under ice cooling. After returning to room temperature and stirring for 24 hours to distill off the solvent, silica gel column chromatography (elution solvent: hexane: ethyl acetate = 100: 0).
→ 50: 50 → 30: 70 → 0: 100).
98 mg of estrone acetate (derivative 4) was obtained.

【0050】[0050]

【実施例28】 <試験例3:アトピー性皮膚炎に対する作用>アトピー
性皮膚炎に悩む20〜42歳のパネラー1群10名が、
上記実施例1〜7の皮膚外用剤(0.02g)を1日朝
晩2回ずつ2ヶ月間患部に塗布し、アトピー性皮膚炎の
改善効果を評価した。評価の基準は、非常に改善した
(評点5)〜改善しない(評点0)、とした。対照とし
ては、本発明の上記一般式(I)で表される化合物又は
その生理的に許容される塩を水に置換したものを用い
た。結果を平均評点として表8に示す。これより、本発
明の皮膚外用剤はアトピー性皮膚炎を改善する作用を有
することがわかる。即ち、本発明の上記一般式(I)で
表される化合物又はその生理的に許容される塩がこのよ
うな作用を有することがわかる。
Example 28 <Test Example 3: Effect on atopic dermatitis> Ten groups of 20-42 year old panelists suffering from atopic dermatitis
The skin external preparations (0.02 g) of the above Examples 1 to 7 were applied to the affected part twice a day and twice a day for 2 months to evaluate the effect of improving atopic dermatitis. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control, a compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof was replaced with water. The results are shown in Table 8 as average scores. This indicates that the external preparation for skin of the present invention has an effect of improving atopic dermatitis. That is, it is understood that the compound represented by the above general formula (I) of the present invention or a physiologically acceptable salt thereof has such an effect.

【0051】[0051]

【表8】 [Table 8]

【0052】[0052]

【実施例29】 <試験例4:湿疹治療作用>吹き出物に悩む19〜29
歳のパネラー1群10名が、上記実施例1〜7の皮膚外
用剤(0.02g)を1日朝晩2回ずつ2ヶ月間塗布
し、湿疹の改善効果を評価した。評価の基準は、非常に
改善した(評点5)〜改善しない(評点0)、とした。
対照としては、本発明の上記一般式(I)で表される化
合物又はその生理的に許容される塩を水に置換したもの
を用いた。結果を平均評点として表9に示す。これよ
り、本発明の皮膚外用剤の有効成分である上記一般式
(I)で表される化合物又はその生理的に許容される塩
が湿疹を改善する作用を有することがわかる。
Example 29 <Test Example 4: Eczema treatment> 19-29 suffering from breakout
Ten year-old panelists in one group applied the skin external preparations (0.02 g) of Examples 1 to 7 twice a day for two months each day for two months to evaluate the eczema improving effect. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0).
As a control, a compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof was replaced with water. The results are shown in Table 9 as average scores. This indicates that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the external preparation for skin of the present invention, has an effect of improving eczema.

【0053】[0053]

【表9】 [Table 9]

【0054】[0054]

【実施例30】 <試験例5:胃液分泌促進作用>麻酔犬を用いて胃液の
分泌促進を見た。即ち、ペントバルビツールで麻酔した
犬の胃に投与装置付き内視鏡を導入し、検体として表1
0に示す本発明の皮膚外用剤の有効成分である上記一般
式(I)で表される化合物又はその生理的に許容される
塩10mgを50%エタノール水溶液200μlに溶解
又は分散させて背部に経皮投与し、その前後の胃液の分
泌を観察して胃液分泌促進作用を評価した。対照は生理
食塩水のみを用いた。評価の基準は、++(評点4):
対照に比べて著しく胃液分泌が増大、+(評点2):対
照に比べて胃液分泌が増大、±(評点1):対照に比べ
てやや分泌が増大、−(評点0):分泌が対照に比べて
増大せず、とした。結果を表10に示す。尚、表10中
の誘導体1〜4は、上記実施例27で製造したものと同
じである。
Example 30 <Test Example 5: Gastric secretion promoting action> The secretion of gastric juice was examined using an anesthetized dog. That is, an endoscope with an administration device was introduced into the stomach of a dog anesthetized with a pentobarbitur, and a sample was prepared as shown in Table 1.
10 mg of a compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the external preparation for skin of the present invention shown in FIG. It was administered dermally, and the secretion of gastric juice before and after the administration was observed to evaluate the gastric secretion promoting action. As a control, only physiological saline was used. Evaluation criteria are ++ (score 4):
Gastric secretion significantly increased compared to the control, + (Score 2): Gastric secretion increased compared to the control, ± (Score 1): Slightly increased compared to the control,-(Score 0): Secreted compared to the control It did not increase in comparison with that. Table 10 shows the results. The derivatives 1 to 4 in Table 10 are the same as those produced in Example 27 above.

【0055】これより、本発明の有効成分である上記一
般式(I)で表される化合物又はその生理的に許容され
る塩は胃液分泌促進作用に優れることがわかる。
From these results, it can be seen that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the present invention, has an excellent gastric secretion promoting action.

【0056】[0056]

【表10】 [Table 10]

【0057】[0057]

【実施例31】 <試験例6:便通・排尿の促進作用>ICRマウスを代
謝ケージで飼育した。投与群は、検体として上記実施例
1〜7の皮膚外用剤を、剃毛した背部皮膚に1g/1日
/1匹、毎日朝夕2回0.5gずつ、7日間塗布して経
皮投与した。最後の投与後24時間の尿と糞の量をモニ
ターした。コントロール群は検体を投与しなかった。各
サンプル1群10匹とした。検体投与群の尿量の総和を
コントロール群の尿量の総和で除した値と検体投与群の
糞量の総和をコントロール群の糞量の総和で除した値と
を表11に示す。これより本発明の上記一般式(I)で
表される化合物又はその生理的に許容される塩は、便通
促進作用及び排尿促進作用(利尿作用)に優れることが
わかる。
Example 31 <Test Example 6: Promotion of bowel movement and urination> ICR mice were bred in metabolic cages. In the administration group, the skin external preparations of Examples 1 to 7 were applied to the shaved back skin as a sample at a rate of 1 g / day / animal, 0.5 g twice daily in the morning and evening, for 7 days, and then transdermally administered. . The amount of urine and feces 24 hours after the last dose was monitored. The control group received no specimen. Each group consisted of 10 animals. Table 11 shows the value obtained by dividing the total urine volume of the sample administration group by the total urine volume of the control group and the value obtained by dividing the total fecal volume of the sample administration group by the total fecal volume of the control group. This shows that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof of the present invention is excellent in the bowel movement promoting action and the urination promoting action (diuretic action).

【0058】[0058]

【表11】 [Table 11]

【0059】[0059]

【発明の効果】本発明によれば、美肌作用、アトピー性
皮膚炎治療作用、湿疹で代表される皮膚炎群治療作用、
皮膚真菌症治療作用、疣贅治療作用、肝炎で代表される
色素沈着症治療作用、尋常性乾癬治療症、老人性乾皮
症、老人性角化腫治療作用、物理的原因による皮膚損傷
治療作用、発毛促進作用、消化液分泌促進作用、発汗促
進作用、便通促進作用、及び利尿作用からなる群から選
ばれる津液作用を改善しうる皮膚外用剤を提供すること
ができる。
According to the present invention, a beautiful skin effect, a therapeutic effect on atopic dermatitis, a therapeutic effect on a dermatitis group represented by eczema,
Treatment for dermatomycosis, treatment for warts, treatment for pigmentation such as hepatitis, treatment for psoriasis vulgaris, treatment for senile xeroderma, senile keratoma, treatment for skin damage due to physical causes It is possible to provide a skin external preparation capable of improving a tsukusu action selected from the group consisting of a hair growth promoting action, a digestive juice secretion promoting action, a sweating promoting action, a bowel movement promoting action, and a diuretic action.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 31/165 ADS A61K 31/165 ADS C07J 1/00 C07J 1/00 (72)発明者 安藤 信裕 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内 (72)発明者 村松 宜江 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内 (72)発明者 河合 充夫 神奈川県横浜市戸塚区柏尾町560 ポーラ 化成工業株式会社戸塚研究所内────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 31/165 ADS A61K 31/165 ADS C07J 1/00 C07J 1/00 (72) Inventor Nobuhiro Ando Takashima, Kanagawa-ku, Yokohama, Kanagawa Prefecture 271-2 Daila Kasei Kogyo Co., Ltd. Yokohama Research Center (72) Inventor Yoshie Muramatsu 27-1 Takashimadai, Kanagawa-ku, Kanagawa-ku, Yokohama-shi, Kanagawa Prefecture Yokohama Co., Ltd. Polar Research Co., Ltd. (72) Inventor Mitsuo Kawai Yokohama-shi, Kanagawa Prefecture 560 Kashio-cho, Totsuka-ku Pola Kasei Kogyo Co., Ltd.

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 下記一般式(I)で表される化合物及び
その生理的に許容される塩からなる群から選ばれる1種
又は2種以上を有効成分とする、津液改善用皮膚外用
剤。 【化1】 [式(I)中、Aは窒素原子、−NR11−、−CR11
又は−CHR11−を表し、Bはカルボニル基、−CR12
−又は−CHR12−を表し、R1、R2、R3、R4
5、R6、R7、R8、R9、R10、R11、及びR12はそ
れぞれ独立に水素原子、水酸基、アルキルオキシ基、ア
シルオキシ基、カルボニル基を形成していてもよい酸素
原子、エステル化されていてもよいカルボキシル基、カ
ルボニル基又は同一化合物内の他の原子と結合していて
もよく、また結合する炭素原子とは多重結合していても
よい低鎖長アルキル基を表し、n、mはそれぞれ独立に
0又は1を表す。]
1. A skin external preparation for improving tsumucus containing one or more active ingredients selected from the group consisting of a compound represented by the following formula (I) and a physiologically acceptable salt thereof. Embedded image [In formula (I), A is a nitrogen atom, -NR 11 -, - CR 11 -
Or -CHR 11 -, B stands carbonyl group, -CR 12
— Or —CHR 12 —, wherein R 1 , R 2 , R 3 , R 4 ,
R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 each independently represent a hydrogen atom, a hydroxyl group, an alkyloxy group, an acyloxy group, or an oxygen which may form a carbonyl group. Atom, a carboxyl group which may be esterified, a carbonyl group or a low chain alkyl group which may be bonded to another atom in the same compound and which may be multiple-bonded to the carbon atom to be bonded. And n and m each independently represent 0 or 1. ]
【請求項2】 前記一般式(I)で表される化合物が、
下記一般式(II)で表されるエストロン、下記一般式
(III)で表されるエストラジオール、下記一般式
(IV)で表されるエストリオール、下記一般式(V)
で表されるアンドロステロン、下記一般式(VI)で表
されるスチルベステロール、下記一般式(VII)で表
される3,4−ビス(4−ヒドロキシフェニル)ヘキサ
ン−2,4−ジエン、下記一般式(VIII)で表され
る4−(N−(4−ヒドロキシフェニル)アミノカルボ
ニル)フェノール、下記一般式(IX)で表されるデオ
キシスチルベステロール、下記一般式(X)で表される
3−(4−ヒドロキシフェニル)−4−フェニルヘキサ
ン−2,4−ジエン、もしくは下記一般式(XI)で表
される4−(N−フェニルアミノカルボニル)フェノー
ル又はこれらの誘導体である、請求項1記載の津液改善
用皮膚外用剤。 【化2】 【化3】 【化4】 【化5】 【化6】 【化7】 【化8】 【化9】 【化10】 【化11】
2. The compound represented by the general formula (I)
Estrone represented by the following general formula (II), estradiol represented by the following general formula (III), estriol represented by the following general formula (IV), and the following general formula (V)
Androsterone represented by the following general formula (VI), stilbesterol represented by the following general formula (VII), 3,4-bis (4-hydroxyphenyl) hexane-2,4-diene represented by the following general formula (VII), 4- (N- (4-hydroxyphenyl) aminocarbonyl) phenol represented by the following general formula (VIII), deoxystilbestrol represented by the following general formula (IX), and represented by the following general formula (X) 3- (4-hydroxyphenyl) -4-phenylhexane-2,4-diene, 4- (N-phenylaminocarbonyl) phenol represented by the following general formula (XI), or a derivative thereof. Item 4. An external skin preparation for tsumugi according to Item 1. Embedded image Embedded image Embedded image Embedded image Embedded image Embedded image Embedded image Embedded image Embedded image Embedded image
【請求項3】 前記一般式(I)で表される化合物及び
その生理的に許容される塩からなる群から選ばれる1種
又は2種以上を0.001〜20重量%含有する、請求
項1又は2記載の津液改善用皮膚外用剤。
3. The composition according to claim 1, which comprises 0.001 to 20% by weight of one or more selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof. 3. A skin external preparation for improving tsumugi according to 1 or 2.
【請求項4】 化粧料である、請求項1〜3のいずれか
に記載の皮膚外用剤。
4. The external preparation for skin according to claim 1, which is a cosmetic.
【請求項5】 医薬である、請求項1〜3のいずれかに
記載の皮膚外用剤。
5. The external preparation for skin according to claim 1, which is a medicament.
【請求項6】 美肌作用、アトピー性皮膚炎治療作用、
皮膚炎群治療作用、皮膚真菌症治療作用、疣贅治療作
用、色素沈着症治療作用、尋常性乾癬治療症、老人性乾
皮症、老人性角化腫治療作用、皮膚損傷治療作用、発毛
促進作用、消化液分泌促進作用、発汗促進作用、便通促
進作用、及び利尿作用からなる群から選ばれる津液作用
の改善用である、請求項1〜5のいずれかに記載の皮膚
外用剤。
6. A beautiful skin effect, an atopic dermatitis treatment effect,
Dermatitis group treatment, dermatomycosis treatment, wart treatment, pigmentation treatment, psoriasis vulgaris, senile xerosis, senile keratoma treatment, skin damage treatment, hair growth The external preparation for skin according to any one of claims 1 to 5, which is used for improving a tsutsuma action selected from the group consisting of a promoting action, a digestive juice secretion promoting action, a sweating promoting action, a bowel movement promoting action, and a diuretic action.
JP26052897A 1996-10-18 1997-09-25 External preparation for skin for improving water (of chinese medicine idea) Pending JPH10175854A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP26052897A JPH10175854A (en) 1996-10-18 1997-09-25 External preparation for skin for improving water (of chinese medicine idea)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27665996 1996-10-18
JP8-276659 1996-10-18
JP26052897A JPH10175854A (en) 1996-10-18 1997-09-25 External preparation for skin for improving water (of chinese medicine idea)

Publications (1)

Publication Number Publication Date
JPH10175854A true JPH10175854A (en) 1998-06-30

Family

ID=26544645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26052897A Pending JPH10175854A (en) 1996-10-18 1997-09-25 External preparation for skin for improving water (of chinese medicine idea)

Country Status (1)

Country Link
JP (1) JPH10175854A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085154A3 (en) * 2000-05-12 2002-08-29 Univ Oregon Health Sciences Method of treating immune pathologies with low dose estrogen
FR2840530A1 (en) * 2002-06-11 2003-12-12 Oreal Cosmetic agent that induces expression of DOPAchrome tautomerase as a protective agent for hair follicle melanocytes in prevention and treatment of hair pigmentation loss
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US7514583B2 (en) 2002-05-31 2009-04-07 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US7629375B2 (en) 2001-07-23 2009-12-08 Johnson & Johnson Consumer Companies, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2011162513A (en) * 2010-02-12 2011-08-25 Sunny Place:Kk Pomegranate seed extract, pharmaceutical composition, food and drink, and cosmetic thereof, and method for use thereof
US8053197B2 (en) 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
AT510867A5 (en) * 2009-03-23 2012-12-15 Sami Labs Ltd MELANGE INHIBITION THROUGH 3,5-DIMETHOXY-4'-HYDROXYSTILENE AND COSMETIC COMPOSITIONS HAVE
US8754133B2 (en) 2001-11-02 2014-06-17 Proteotech, Inc. Compounds, compositions and methods for the treatment of inflammatory diseases

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579006B2 (en) 2000-05-12 2009-08-25 Oregon Health And Science University Method of treating immune pathologies with low dose estrogen
AU2001259847B2 (en) * 2000-05-12 2006-02-02 Oregon Health And Science University Method of treating immune pathologies with low dose estrogen
AU2001259847B8 (en) * 2000-05-12 2006-02-23 Oregon Health And Science University Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
WO2001085154A3 (en) * 2000-05-12 2002-08-29 Univ Oregon Health Sciences Method of treating immune pathologies with low dose estrogen
US7629375B2 (en) 2001-07-23 2009-12-08 Johnson & Johnson Consumer Companies, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
US8754133B2 (en) 2001-11-02 2014-06-17 Proteotech, Inc. Compounds, compositions and methods for the treatment of inflammatory diseases
US7514583B2 (en) 2002-05-31 2009-04-07 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US8163957B2 (en) 2002-05-31 2012-04-24 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
WO2003103568A3 (en) * 2002-06-11 2004-05-06 Oreal Use of an agent inducing dopachrome tautomerase (trp-2) expression as protecting agent for hair follicle melanocytes and uses thereof
FR2840530A1 (en) * 2002-06-11 2003-12-12 Oreal Cosmetic agent that induces expression of DOPAchrome tautomerase as a protective agent for hair follicle melanocytes in prevention and treatment of hair pigmentation loss
US8053197B2 (en) 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
AT510867A5 (en) * 2009-03-23 2012-12-15 Sami Labs Ltd MELANGE INHIBITION THROUGH 3,5-DIMETHOXY-4'-HYDROXYSTILENE AND COSMETIC COMPOSITIONS HAVE
JP2011162513A (en) * 2010-02-12 2011-08-25 Sunny Place:Kk Pomegranate seed extract, pharmaceutical composition, food and drink, and cosmetic thereof, and method for use thereof

Similar Documents

Publication Publication Date Title
JP3631259B2 (en) Pharmaceutical composition
CA2173689C (en) Use of an alkaline-earth metal salt as a tnf-.alpha. or p substance inhibitor in a topical composition and composition thus obtained
JPH10114649A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
JP3409165B2 (en) Hair restorer and its production method
WO2018175796A1 (en) Skin care compositions and methods
HU218921B (en) Topical use of anorganic salt of stroncium (ii) for producing pharmaceutical compositions for treating neurogen skin-diseases
JP2010520232A (en) External preparation composition containing ginseng extract and its use as a skin moisturizing cosmetic
JPH07300412A (en) Active oxygen remover and composition containing the same
JPH10175854A (en) External preparation for skin for improving water (of chinese medicine idea)
JP6796601B2 (en) Cosmetic methods and therapeutic uses to reduce fat
JPH10120579A (en) Skin preparation for improving sputum for external use
KR101503158B1 (en) Cosmetic composition for improving skin wrinkle and enhancing elasticity
JPH10175859A (en) External preparation for skin for improving water (of chinese medicine idea)
JPH10120558A (en) Skin preparation for improving sputum for external use
JP4018764B2 (en) Skin preparation for improving tsunami
JP2023038290A (en) Leucine derivatives, compositions comprising the same, and applications thereof
JP4100805B2 (en) Cosmetics
WO2017111069A1 (en) Antipruritic
JPH10175868A (en) Water (of chinese medicine idea) improving composition
JPH10120561A (en) Skin preparation for improving sputum for external use
JPH10175852A (en) Water (of chinese medicine idea) improver and composition for oral administration containing the same
JPH10114665A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
JP4049406B2 (en) Tsu fluid improving agent and composition for oral administration containing the same
JPH0296581A (en) Biotin ester and skin ointment and hair tonic using the ester
JP5956916B2 (en) Anti-inflammatory agent

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070703

A977 Report on retrieval

Effective date: 20070705

Free format text: JAPANESE INTERMEDIATE CODE: A971007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071030